Form 4 for ACRS Aclaris Therapeutics, Inc.
Accepted 2024-01-03 00:00:00 ET · period of report 2024-01-01 · accession 0001209191-24-000425 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-03 | 2024-01-01 | ACRS | Balthaser Kevin | CFO | F - Tax | $1.05 | -2,536 | 20.4K | -11% | -$2,663 |
| D | 2024-01-03 | 2024-01-01 | ACRS | Balthaser Kevin | CFO | M - OptEx | — | +7,500 | 23.0K | +49% | — |
| D | 2024-01-03 | 2024-01-01 | ACRS | Balthaser Kevin | CFO | M - OptEx | $0.00 | -7,500 | 22.5K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-01 | F | D | 2,536 | $1.05 | 20,425 | D | — | — | |
| 2 | Common | Common Stock | 2024-01-01 | M | A | 7,500 | — | 22,961 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. |
| 3 | Derivative | Restricted Stock Units | 2024-01-01 | M | D | 7,500 | $0.00 | 22,500 | D | — · — to — | 7,500 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. (F3) On February 1, 2023, the Reporting Person was granted 30,000 restricted stock units. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. |